More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback